4-(Dimethylamino)phenol

CAS No. 619-60-3

4-(Dimethylamino)phenol( —— )

Catalog No. M35792 CAS No. 619-60-3

4-(Dimethylamino)phenol enhances extracellular lactate dehydrogenase (LDH) levels without significant effects on gluconeogenesis.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G 27 In Stock

Biological Information

  • Product Name
    4-(Dimethylamino)phenol
  • Note
    Research use only, not for human use.
  • Brief Description
    4-(Dimethylamino)phenol enhances extracellular lactate dehydrogenase (LDH) levels without significant effects on gluconeogenesis.
  • Description
    4-(Dimethylamino)phenol increases the extracellular lactate dehydrogenase (LDH) without markedly affecting gluconeogenesis. 4-(Dimethylamino)phenol cannot decreases the ATP content until the membrane becomes permeable to LDH.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Others
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    619-60-3
  • Formula Weight
    137.18
  • Molecular Formula
    C8H11NO
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 100 mg/mL (728.97 mM; Ultrasonic (<60°C)
  • SMILES
    CN(C)c1ccc(O)cc1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Szinicz LL, et al. Effects of 4-dimethylaminophenol in rat kidneys, isolated rat kidney tubules and hepatocytes. Xenobiotica. 1980;10(7-8):611-620.?
molnova catalog
related products
  • WDR5-0102

    WDR5-0102 is a compound that inhibits the WDR5-MLL1 interface (K dis = 7 μM, K d = 4 μM), selectively reducing MLL1 HMT activity without affecting the human H3K4 methyltransferase SETD7 or other HMTs, including G9a, EHMT1, SUV39H2, SETD8, PRMT3, and PRMT5.

  • Substance P 1-7

    Substance P 1-7 is the major bioactive metabolite formed after proteolytic degradation of the tachykinin substance P (SP)with anti-inflammatory anti-nociceptive and anti-hyperalgesic effects.

  • TNF-α (46-65), human...

    TNF-α (46-65), human (TFA) is a peptide of human TNF-α.